WAVE Life Sciences Ltd. (NASDAQ:WVE) will be discussing 3Q20 financial results with the investment community.on 9th November 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.wavelifesciences.com
Earnings Expectation
WAVE Life Sciences Ltd. is expected to report third quarter earnings results, before market open, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.69 per share from revenue of $ 11.55 million. Looking ahead, the full year loss are expected at $ 3.66 per share on the revenues of $ 31.07 million.
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system.
